ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study

June 29, 2012

Digital Immunoassay PSA Test May Predict Cancer Recurrence

October 28, 2011

Upton Prefers Keeping Bioassay Program In NCI

May 12, 1978

New Compounds To Treat Gleevec-Resistant CML

January 26, 2007

Majority Of U.S. Cancer Patients Receive High-Quality Care, ASCO Study Finds

July 29, 2005

In Brief: Henney Permanent NCI Deputy Director; 17 Regional Cooperative Group Applications Get First Review

February 5, 1982